About the Company
Catalyst is a clinical-stage biopharmaceutical company leveraging exceptional science to discover and develop essential medicines.
Catalyst is focused on creating and commercializing novel medicines to address serious medical conditions for patients who need new or better treatment options.
Engineered proteases can efficiently initiate or regulate protease-driven biological cascades and can act on hundreds to thousands of target molecules.
While our scientific approach is singularly focused on protease therapeutic agents, our opportunities are many. Learn more about Our Pipeline.
A protease is an enzyme that cleaves target proteins. Learn more about Our Science.
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the pricing of an underwritten public offering of...
Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
Korean Ministry of Food and Drug Safety Approves Omitting Cohort 4 and Dosing Cohort 5 with Six Daily Subcutaneous Doses of Next-Generation Coagulation Factor IX Current lower doses are predicted to achieve normal Factor IX levels SOUTH SAN FRANCISCO,...
Former Novo Nordisk Executive Strengthens Catalyst’s Hemophilia Expertise SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the appointment...
Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference
Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO),...